Quoin Pharmaceuticals Launches 'NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Core Viewpoint - Quoin Pharmaceuticals has launched the "NETHERTON NOW" campaign to raise awareness about Netherton Syndrome, a genetic disease with significant misdiagnosis rates and high mortality among affected infants [1][4]. Company Overview - Quoin Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company focused on developing treatments for rare and orphan diseases, including Netherton Syndrome [9]. - The company is conducting four ongoing clinical studies to evaluate the safety and efficacy of its product QRX003 for Netherton Syndrome [3]. Netherton Syndrome - Netherton Syndrome is characterized by severe skin shedding, red scaly skin, and complications such as dehydration, infections, asthma, and allergies [2][7]. - The condition is caused by a mutation in the SPINK5 gene, leading to significant challenges for patients and their families [6]. QRX003 Product Development - QRX003 is a topical lotion designed to improve skin barrier function and normalize skin shedding, addressing the core issues of Netherton Syndrome [8]. - Recent clinical data has shown promising results for QRX003, with photographic evidence demonstrating significant skin improvement after 12 weeks of treatment [3]. Campaign Objectives - The "NETHERTON NOW" campaign aims to increase public awareness, foster advocacy, and provide educational resources about Netherton Syndrome [4][5]. - The campaign also serves as a platform for patients and families to share experiences and connect with one another [3]. Future Directions - Quoin is preparing for a "whole body" clinical study of QRX003, which has received FDA clearance, marking a significant step in the product's development [3]. - The company is committed to building a robust data package to support regulatory approval in the US, EU, and other countries [3].